NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.78 +0.76 (+0.97%) GOLD FUTURES
2,390.70 +30.80 (+1.31%) DOW
39,842.53 +284.42 (+0.72%) Bitcoin GBP
51,604.44 +3,189.48 (+6.59%)
Coloplast A/S (CBHD.DE)
| Previous close | 113.50 |
| Open | 112.15 |
| Bid | 111.80 x 200000 |
| Ask | 112.70 x 7800 |
| Day's range | 110.85 - 112.50 |
| 52-week range | 92.50 - 130.95 |
| Volume | |
| Avg. volume | 340 |
| Market cap | 24.92B |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | 37.31 |
| EPS (TTM) | 3.01 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | 2.82 (2.48%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | N/A |
Globe NewswireColoplast expands its Luja™ portfolio with next generation catheter for women
Luja Female Luja Female is an intermittent catheter that enables complete bladder emptying in one free flow, aiming to reduce the risk of urinary tract infections. The female intermittent catheter enables complete bladder emptying in one free flow1, aiming to reduce the risk of urinary tract infections2. Following the successful launch of Luja with Micro-hole Zone Technology, a next generation intermittent catheter for men, Coloplast is now launching Luja for women. “So far, we have received gre
GlobeNewswireColoplast strengthens ostomy care portfolio with three significant product launches
Heylo Heylo is the world's first digital leakage notification system. SenSuraMio_Black SenSura Mio in black developed to provide more product choice for people living with a stoma. The company has received reimbursement approval in the UK for Heylo™, the world’s first digital leakage notification system, and expands its SenSura® Mio ostomy range with two new products. As part of our 2025 strategy, Strive25, we set an ambition to significantly raise the standard of care for our users and bring ne
Globe NewswireColoplast A/S - Announcement no. 02/2024 - Interim Financial Report, H1 2023/24
H1 2023/24Interim financial results, H1 2023/241 October 2023 - 31 March 2024 Coloplast delivered a solid Q2 with 8% organic growth and an EBIT margin1) of 27%. Reported revenue in DKK grew 9% with 4%-points contribution from Kerecis (underlying growth of around 35%), partly offset by currencies. Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice and Respiratory Care 13%, Advanced Wound Care 8% (Advanced Wound Dressings 8%) and Interventional Urology 5%.Continued go
